Home › Pancreatic Cancer › Tennessee › Nashville
Pancreatic Cancer clinical trials in Nashville, TN
39 studies for Pancreatic Cancer are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 3
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
RecruitingPhase 1
- PHN-012-001 Site, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RecruitingPhase 2/3
- Henry-Joyce Cancer Clinic, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
- Investigative Site US039, Nashville
- Investigative Site US060, Nashville
- Investigative Site US070, Nashville
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RecruitingPhase 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Center, Nashville
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
RecruitingObservational study
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
RecruitingPhase 2
- Sarah Cannon Research Institute, Nashville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- Vanderbilt - Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Investigative Site #102, Nashville
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
RecruitingPhase 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RecruitingPhase 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingPhase 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RecruitingObservational study
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
Recruiting
- Vanderbilt University Medical Center, Nashville
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
RecruitingPhase 2
- Ohio State University-Telemedicine, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #6, Nashville
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecruitingPhase 1
- Vanderbilt University Medical Center, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
About Pancreatic Cancer
The pancreas is a gland behind your stomach that produces insulin. Pancreatic cancer is hard to catch early. Find out about risk factors and symptoms.
More about Pancreatic Cancer on MedlinePlus
Pancreatic Cancer trials in other cities
- Houston, TX61 studies
- New York City, NY60 studies
- Boston, MA43 studies
- Los Angeles, CA35 studies
- St. Louis, MO33 studies
- Arlington, VA33 studies
- Baltimore, MD31 studies
- San Antonio, TX31 studies
- Philadelphia, PA26 studies
- Tampa, FL26 studies
- Durham, NC24 studies
- San Diego, CA24 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
- Multiple Myeloma32 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.